Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CINDY E OWEN

Allopathic & Osteopathic Physicians Dermatology

NPI
1598803819
CMS profile
117868
Location
LOUISVILLE, KY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$2,410.66

70 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,449.80 66
Travel and Lodging $860.87 3
Education $99.99 1

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
PFIZER INC. $1,556.01 9
Novartis Pharmaceuticals Corporation $284.47 20
Janssen Biotech, Inc. $254.37 21
Lilly USA, LLC $144.30 9
Amgen Inc. $67.04 4
AbbVie, Inc. $40.70 3
Ortho Dermatologics, a division of Bausch Health US, LLC $32.02 2
UCB, Inc. $17.50 1
DERMIRA, INC. $14.25 1

Page 1 of 2; records 1–50 of 70 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CINDY E OWEN

NPI 1598803819 · CMS profile ID 117868

Allopathic & Osteopathic Physicians / Dermatology

LOUISVILLE, KY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 2; records 1–50 of 70 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1598803819?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CINDY E OWEN, NPI 1598803819, CMS profile ID 117868. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 70 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1598803819?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). CINDY E OWEN, NPI 1598803819, CMS profile ID 117868. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 70 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1598803819?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
CINDY E OWEN, NPI 1598803819, CMS profile ID 117868, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 70 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1598803819?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

70 matching records · $2,410.66 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 70 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 70.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $14.5312/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 708393129 CMS
Amgen Inc. $13.0612/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662258797 CMS
Janssen Biotech, Inc. $13.1112/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 708393131 CMS
Janssen Biotech, Inc. $5.5112/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658628231 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $15.5812/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684597153 CMS
Novartis Pharmaceuticals Corporation $16.9312/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659807053 CMS
UCB, Inc. $17.5011/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688331537 CMS
Janssen Biotech, Inc. $11.1511/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658628227 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $16.4411/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684597151 CMS
Lilly USA, LLC $12.3011/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657741225 CMS
Janssen Biotech, Inc. $0.9511/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658628225 CMS
Novartis Pharmaceuticals Corporation $13.0311/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659807049 CMS
PFIZER INC. $228.9410/24/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673854677 CMS
PFIZER INC. $665.8410/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673854679 CMS
PFIZER INC. $256.9710/24/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673854681 CMS
PFIZER INC. $374.9610/24/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673854683 CMS
Lilly USA, LLC $20.8210/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657748179 CMS
Novartis Pharmaceuticals Corporation $19.5410/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659806989 CMS
Janssen Biotech, Inc. $8.8909/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658628221 CMS
Novartis Pharmaceuticals Corporation $16.1809/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659807041 CMS
Lilly USA, LLC $21.2609/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657730847 CMS
Novartis Pharmaceuticals Corporation $20.0009/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659807037 CMS
Janssen Biotech, Inc. $11.7008/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658628211 CMS
Lilly USA, LLC $23.9208/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657748177 CMS
Janssen Biotech, Inc. $5.4208/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658628199 CMS
AbbVie, Inc. $11.5708/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648273847 CMS
Janssen Biotech, Inc. $11.9307/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658628193 CMS
Lilly USA, LLC $5.2407/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657734293 CMS
Novartis Pharmaceuticals Corporation $14.6907/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659807025 CMS
Amgen Inc. $13.8807/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662258795 CMS
Novartis Pharmaceuticals Corporation $21.2207/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659807021 CMS
DERMIRA, INC. $14.2507/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703887165 CMS
AbbVie, Inc. $18.1706/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648273889 CMS
Janssen Biotech, Inc. $99.9906/13/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658628179 CMS
Janssen Biotech, Inc. $6.2406/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658628169 CMS
Lilly USA, LLC $19.1306/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657755017 CMS
Janssen Biotech, Inc. $10.4806/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658628161 CMS
Amgen Inc. $27.6705/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662258793 CMS
Janssen Biotech, Inc. $0.4505/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658628157 CMS
Novartis Pharmaceuticals Corporation $13.4505/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659807029 CMS
Janssen Biotech, Inc. $1.0605/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658628153 CMS
Janssen Biotech, Inc. $9.5904/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658628141 CMS
Lilly USA, LLC $12.4804/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657748175 CMS
AbbVie, Inc. $10.9604/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648274075 CMS
Novartis Pharmaceuticals Corporation $11.0604/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659807033 CMS
Janssen Biotech, Inc. $12.5204/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658628139 CMS
PFIZER INC. $11.3204/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673244427 CMS
Novartis Pharmaceuticals Corporation $12.8304/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659807013 CMS
Janssen Biotech, Inc. $0.9404/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658628131 CMS
Novartis Pharmaceuticals Corporation $8.8003/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659807011 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,410.66 70
PY2020 $4,329.13 26
PY2021 $1,014.27 67
PY2022 $1,019.13 72
PY2023 $883.07 50
PY2024 $1,269.36 78
PY2025 $1,140.98 54

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $848,779.58 205
PY2024 Principal investigator $465,404.25 284
PY2023 Principal investigator $512,761.61 145
PY2022 Recipient $8.00 1
PY2022 Principal investigator $318,333.10 76
PY2021 Recipient $579.11 2
PY2021 Principal investigator $303,603.63 109
PY2020 Recipient $5,811.05 7
PY2020 Principal investigator $509,738.55 72
PY2019 Recipient $47,562.83 13
PY2019 Principal investigator $1,244,974.63 84

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

77 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $3,358.00 12/26/2022 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Oral Tablet Formulation of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis No dispute reported 06/30/2026 885250671
Principal investigator 1 Janssen Research & Development, LLC $6,957.00 12/26/2022 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Oral Tablet Formulation of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis No dispute reported 06/30/2026 885250673
Principal investigator 1 Eli Lilly and Company $706.00 12/15/2022 Non-covered Recipient Entity
ARTHRITIS CONSULTANTS INC
AN OPEN-LABEL, STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS PREVIOUSLY TREATED WITH DUPILUMAB No dispute reported 06/30/2026 917823103
Principal investigator 1 Dermavant Sciences, Inc. $3,597.00 12/14/2022 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937433417
Principal investigator 1 Dermavant Sciences, Inc. $278.46 12/14/2022 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937433419
Principal investigator 1 Dermavant Sciences, Inc. $278.46 12/14/2022 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937433421
Principal investigator 1 Dermavant Sciences, Inc. $278.46 12/14/2022 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937433423
Principal investigator 1 Dermavant Sciences, Inc. $278.46 12/14/2022 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937433425
Principal investigator 1 Dermavant Sciences, Inc. $5,000.00 12/14/2022 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937433427
Principal investigator 1 Dermavant Sciences, Inc. $1,287.16 12/14/2022 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937433429
Principal investigator 1 Dermavant Sciences, Inc. $1,287.16 12/14/2022 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937433431
Principal investigator 1 Dermavant Sciences, Inc. $1,287.16 12/14/2022 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937433433
Principal investigator 1 Dermavant Sciences, Inc. $1,248.48 12/14/2022 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937433435
Principal investigator 1 Dermavant Sciences, Inc. $1,004.28 12/14/2022 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937433437
Principal investigator 1 Dermavant Sciences, Inc. $1,004.28 12/14/2022 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937433439
Principal investigator 1 Dermavant Sciences, Inc. $1,004.28 12/14/2022 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937433441
Principal investigator 1 Dermavant Sciences, Inc. $1,004.28 12/14/2022 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937433443
Principal investigator 1 Dermavant Sciences, Inc. $1,004.28 12/14/2022 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937433445
Principal investigator 1 Dermavant Sciences, Inc. $1,204.28 12/14/2022 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937433447
Principal investigator 1 Dermavant Sciences, Inc. $1,204.28 12/14/2022 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937433449
Principal investigator 1 GENZYME CORPORATION $4,460.72 12/12/2022 Non-covered Recipient Entity
Scott Health Services Llc Ds Research
POC - Atopic dermatitis No dispute reported 06/30/2026 935603429
Principal investigator 1 GENZYME CORPORATION $3,590.00 12/05/2022 Non-covered Recipient Entity
Scott Health Services Llc Ds Research
POC - Atopic dermatitis No dispute reported 06/30/2026 935603421
Principal investigator 1 Bausch Health US, LLC $500.00 12/02/2022 Non-covered Recipient Entity
DS RESEARCH
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF IDP-126 GEL TO EPIDUO? FORTE GEL (0.3% ADAPALENE/2.5% BPO), IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 960342413
Principal investigator 1 Bausch Health US, LLC $750.00 12/02/2022 Non-covered Recipient Entity
DS RESEARCH
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF IDP-126 GEL TO EPIDUO? FORTE GEL (0.3% ADAPALENE/2.5% BPO), IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 960342415
Principal investigator 1 Bausch Health US, LLC $10,025.12 12/02/2022 Non-covered Recipient Entity
DS RESEARCH
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF IDP-126 GEL TO EPIDUO? FORTE GEL (0.3% ADAPALENE/2.5% BPO), IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 960342417
Principal investigator 1 SANOFI US SERVICES INC. $5,000.00 12/01/2022 Non-covered Recipient Entity
Scott Health Services Llc Ds Research
A Phase IIb, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Dose Ranging Study of a Subcutaneous Anti-OX40L Monoclonal Antibody (KY1005) in Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 935609235
Principal investigator 1 Horizon Therapeutics plc $8,490.00 11/28/2022 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
A PHASE 2A, OPEN LABEL, PROOF OF CONCEPT TRIAL OF DAXDILIMAB FOR THE TREATMENT OF MODERATE TO SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 937594353
Principal investigator 1 Janssen Research & Development, LLC $27,470.00 11/28/2022 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Oral Tablet Formulation of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis No dispute reported 06/30/2026 885250665
Principal investigator 1 SANOFI US SERVICES INC. $1,277.00 11/22/2022 Non-covered Recipient Entity
Scott Health Services Llc Ds Research
A Phase IIb, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Dose Ranging Study of a Subcutaneous Anti-OX40L Monoclonal Antibody (KY1005) in Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 935609257
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 11/07/2022 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Oral Tablet Formulation of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis No dispute reported 06/30/2026 885250663
Principal investigator 1 Janssen Research & Development, LLC $4,500.00 11/07/2022 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Oral Tablet Formulation of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis No dispute reported 06/30/2026 885250667
Principal investigator 1 Janssen Research & Development, LLC $50.00 11/07/2022 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Oral Tablet Formulation of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis No dispute reported 06/30/2026 885250669
Principal investigator 1 Journey Medical Corporation $500.00 11/04/2022 Non-covered Recipient Entity
Scott Health Services, LLC
DFD-29-CD-005 No dispute reported 06/30/2026 923103617
Principal investigator 1 GENZYME CORPORATION $4,495.87 11/02/2022 Non-covered Recipient Entity
Scott Health Services Llc Ds Research
POC - Atopic dermatitis No dispute reported 06/30/2026 935603387
Principal investigator 1 SANOFI US SERVICES INC. $3,590.00 11/02/2022 Non-covered Recipient Entity
Scott Health Services Llc Ds Research
Master Protocol of Two Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Studies to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Chronic Pruritus of Unknown Origin (CPUO) No dispute reported 06/30/2026 935603377
Principal investigator 1 Janssen Research & Development, LLC $2,108.00 10/27/2022 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Oral Tablet Formulation of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis No dispute reported 06/30/2026 885250661
Principal investigator 1 Journey Medical Corporation $60,500.00 10/20/2022 Non-covered Recipient Entity
Scott Health Services, LLC
DFD-29-CD-005 No dispute reported 06/30/2026 923103601
Principal investigator 1 Journey Medical Corporation $3,597.00 09/22/2022 Non-covered Recipient Entity
Scott Health Services, LLC
DFD-29-CD-005 No dispute reported 06/30/2026 923103897
Principal investigator 1 GENZYME CORPORATION $3,947.00 08/08/2022 Non-covered Recipient Entity
Scott Health Services Llc Ds Research
POC - Atopic dermatitis No dispute reported 06/30/2026 935603314
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $211.02 07/22/2022 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 949996519
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $148.38 07/22/2022 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 949996521
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $207.45 07/22/2022 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 949996523
Principal investigator 1 GENZYME CORPORATION $1,500.00 07/18/2022 Non-covered Recipient Entity
Scott Health Services Llc Ds Research
POC - Atopic dermatitis No dispute reported 06/30/2026 935603323
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $148.38 07/15/2022 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 949996525
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $211.02 07/15/2022 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 949996527
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $217.62 07/15/2022 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 949996529
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $207.45 07/15/2022 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 949996531
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $97.20 07/15/2022 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 949996533
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $18.30 07/15/2022 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 949996535
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $148.38 07/15/2022 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 949996537
Principal investigator 1 SANOFI US SERVICES INC. $490.00 07/12/2022 Non-covered Recipient Entity
Scott Health Services Llc Ds Research
A Phase IIb, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Dose Ranging Study of a Subcutaneous Anti-OX40L Monoclonal Antibody (KY1005) in Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 935609031
Recipient Eli Lilly and Company $8.00 07/11/2022 Covered Recipient Physician A MULTICENTER, OPEN-LABEL, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 917806697
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $1,559.61 06/17/2022 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 949996549
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $515.97 06/17/2022 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 949996551
Principal investigator 1 Eli Lilly and Company $3,819.00 06/14/2022 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 917840093
Principal investigator 1 GENZYME CORPORATION $9,500.00 06/13/2022 Non-covered Recipient Entity
Scott Health Services Llc Ds Research
POC - Atopic dermatitis No dispute reported 06/30/2026 935603331
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $1,732.90 06/13/2022 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 949996553
Principal investigator 1 Journey Medical Corporation $4,000.00 06/08/2022 Non-covered Recipient Entity
Scott Health Services, LLC
DFD-29-CD-005 No dispute reported 06/30/2026 923102273
Principal investigator 1 Eli Lilly and Company $1,250.00 06/07/2022 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
A PHASE 1, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SUBCUTANEOUS LY3471851 IN PATIENTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 917840867
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,095.00 06/06/2022 Non-covered Recipient Entity
Dermatology Specialists Research-kentucky
Phase II Umbrella AD - A Phase 2, Randomized, Double-blinded, Placebo-controlled, 5 Parallel-group Study of BMS-986166 or Branebrutinib for the Treatment of Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 933191633
Principal investigator 1 Janssen Research & Development, LLC $4,500.00 05/16/2022 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
A Phase 2a Multi Center Randomized Double Blind Placebo Controlled Proof of Concept Study to Evaluate the Efficacy Safety and Tolerability of JNJ64304500 in Patients with Alopecia Areata No dispute reported 06/30/2026 885250659
Principal investigator 1 PFIZER INC. $2,800.00 05/06/2022 Non-covered Recipient Entity
Scott Health Services LLC
A PHASE 2A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 16WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF PF06650833 PF06700841 AND PF06826647 IN ADULTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 949744769
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $515.97 04/26/2022 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 949996555
Principal investigator 1 Bausch Health US, LLC $13,135.90 04/22/2022 Non-covered Recipient Entity
DS RESEARCH
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF IDP-126 GEL TO EPIDUO? FORTE GEL (0.3% ADAPALENE/2.5% BPO), IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 960342411
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $4,209.66 04/14/2022 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 949996557
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $500.00 04/05/2022 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 949996559
Principal investigator 1 Eli Lilly and Company $13,626.00 03/22/2022 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 917841025
Principal investigator 1 Eli Lilly and Company $523.00 03/08/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS RESEARCH
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 917824861
Principal investigator 1 Eli Lilly and Company $17,682.00 03/01/2022 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
A PHASE 1, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SUBCUTANEOUS LY3471851 IN PATIENTS WITH PSORIASIS No dispute reported 06/30/2026 917840855
Principal investigator 1 Eli Lilly and Company $6,285.00 02/15/2022 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
A MULTICENTER, LONG-TERM EXTENSION TO EVALUATE THE LONG-TERM SAFETY AND MAINTENANCE OF TREATMENT EFFECT OF LY3074828 IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS OASIS-3 No dispute reported 06/30/2026 917840861
Principal investigator 1 SANOFI US SERVICES INC. $11,400.00 02/14/2022 Non-covered Recipient Entity
Scott Health Services Llc Ds Research
Master Protocol of Two Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Studies to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Chronic Pruritus of Unknown Origin (CPUO) No dispute reported 06/30/2026 935603287
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $3,500.00 02/10/2022 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 949996561
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $1,000.00 02/10/2022 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 949996563
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $500.00 02/10/2022 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 949996565
Principal investigator 1 Eli Lilly and Company $117.00 02/08/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS RESEARCH
A MULTICENTER, OPEN-LABEL, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 917824473
Principal investigator 1 Eli Lilly and Company $14,103.00 02/08/2022 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
A MULTICENTER, OPEN-LABEL, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 917841019
Principal investigator 1 Bausch Health US, LLC $17,735.42 01/14/2022 Non-covered Recipient Entity
DS RESEARCH
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF IDP-126 GEL TO EPIDUO? FORTE GEL (0.3% ADAPALENE/2.5% BPO), IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 960342409